



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien


T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



Ranibizumab
As of 1st January 2020 is FDA approved for treating:

Macular Degeneration
Macular Edema
Diabetic Macular Edema
Diabetic Retinopathy

Myopic Choroidal Neovascularization

FDA Approval: Yes (First approved June 20, 2006)
Brand name: Lucentis
Generic name: Ranibizumab
Dosage form: Injection
Company: Genentech, Inc.
Dose: 0.5 mg/0.5 mL
Ranibizumab Biosimilar – Research Grade [ICH4031]

ichor.bio
ICH 4031 (ICH4031) (ICH4031)

Ranibizumab Biosimilar – Research Grade [ICH4031]

Description

Bulk Ranibizumab Biosimilar – Research Grade

Product Benefits:

ichorbio's Ranibizumab Biosimilar – Research Grade is manufactured in a cGMP compliant facility. ichorbio: the best antibodies for *in vivo* research.

Size:

ichorbio's research grade ranibizumab biosimilar is available in the following sizes:

5mg, 10mg, 20mg, 50mg

ichorbio regularly manufactures bulk multi-gram amounts of our ranibizumab biosimilar – please contact us for pricing.

Target:

VEGF-A

Clone:

n/a

Isotype:

IgG1 kappa

Other Names:

Vascular endothelial growth factor A, VPF, Vascular Permeability Factor

Host:

Humanized

Species Reactivity:

Human

Specificity:

Detects human VEGF. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Ranibizumab. ichorbio's ranibizumab biosimilar is for research use only (RUO).

Purification Method:

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background:

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by CHO expression system.

Concentration:

1.0 – 5.0 mg/ml

Formulation:

Sterile, colorless to pale yellow solution containing histidine hydrochloride, 10% trehalose dihydrate and Tween 20. pH 5.5. BSA and Azide free.

Purity:

>95% by SDS-PAGE and HPLC

Endotoxin:

? 0.75 EU/mg as determined by the LAL method

Storage:

Ranibizumab Biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Applications:

Functional Assays

Application Notes:

Each investigator should determine their own optimal working dilution for specific applications.

Use:

ichorbio's ranibizumab biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Isotype Control:

[Bulk Human IgG1 Isotype Control \(IB1\) \[ICH2254\]](#)